Does TROP2 expression influence clinical decision-making for TNBC currently?

At this time, TROP2 IHC expression does not guide treatment selection for TROP2-directed ADCs in TNBC clinical practice. Exploratory biomarker analyses from ASCENT and TROPiCS-02 demonstrated that benefit from sacituzumab govitecan was observed across a range of TROP2 expression levels, without a cl...